Modality
Nanobody
MOA
BCL-2i
Target
CD20
Pathway
Fibrosis
OCD
Development Pipeline
Preclinical
~Jan 2011
→ ~Apr 2012
Phase 1
~Jul 2012
→ ~Oct 2013
Phase 2
~Jan 2014
→ ~Apr 2015
Phase 3
~Jul 2015
→ ~Oct 2016
NDA/BLA
~Jan 2017
→ ~Apr 2018
Approved
Jul 2018
→ Feb 2026
ApprovedCurrent
NCT05689347
1,144 pts·OCD
2019-11→2026-02·Completed
NCT07513200
333 pts·OCD
2018-07→2025-04·Completed
1,477 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2025-04-1911mo agoPh3 Readout· OCD
2026-02-231mo agoPh3 Readout· OCD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2025-04-19 · 11mo ago
OCD
Ph3 Readout
2026-02-23 · 1mo ago
OCD
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05689347 | Approved | OCD | Completed | 1144 | UPCR |
| NCT07513200 | Approved | OCD | Completed | 333 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |